JCI Insight 5(17):e140532 Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X et al (2018) Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Many people who switch report positive outcomes, including greater weight loss and the convenience of once-weekly injections
The master cell cycle checkpoint kinase ATM increases 80% in breast cancer cells and 120% in prostate cells
The 12mg dose achieved 17.5% reduction at just 24 weeks, progressing to 24.2% at 48 weeks
In the ever-evolving landscape of medical science, certain discoveries stand out not just for their initial impact, but for their ability to continually reveal new and unexpected benefits
These will still apply, even if you are working with Ozempic or Wegovy patients